GlaxoSmithKline blood cancer treatment meets primary objective in clinical trial

Writer, Stock Market Wire
Friday, August 23, 2019 - 07:16

GlaxoSmithKline said a clinical study of its blood cancer treatment had met its primary goal.

'The two-arm study met its primary objective and demonstrated a clinically meaningful overall response rate with belantamab mafodotin in the patient population, the company said. 'The safety and tolerability profile was consistent with that observed in DREAMM-1, the first time in human study of belantamab mafodotin.'

The data from the study would be the basis for regulatory filings starting later this year,' it added.

'I am pleased with the results of the DREAMM-2 study and excited about what these data could mean for patients with multiple myeloma who have exhausted other lines of treatment,' said Dr Hal Barron, Chief Scientific Officer and President R&D, GSK .


Related content

Broker Forecast - UBS issues a broker note on GlaxoSmithKline PLC

UBS today upgrades its investment rating on GlaxoSmithKline PLC (LON:GSK) to buy (from neutral) and raised its price target to 1900p (from 1610p).

Broker Forecasts...

Thu, 21/11/2019 - 09:50


Four stocks priced for perfection and likely to disappoint investors

Author: 

Controversial Brexiteer hedge fund manager Crispin Odey is fond of saying that cycles never die, or what goes up inevitably comes back down. What this...

Thu, 14/11/2019 - 00:00


Broker Forecast - Liberum Capital issues a broker note on GlaxoSmithKline PLC

Liberum Capital today reaffirms its hold investment rating on GlaxoSmithKline PLC (LON:GSK) and raised its price target to 1890p (from 1510p).

Broker Forecasts data provided...

Mon, 04/11/2019 - 10:30


Broker Forecast - Barclays Capital issues a broker note on GlaxoSmithKline PLC

Barclays Capital today reaffirms its equal weight investment rating on GlaxoSmithKline PLC (LON:GSK) and raised its price target to 1650p (from 1600p).

Broker Forecasts data...

Fri, 01/11/2019 - 10:10


Broker Forecast - DZ Bank issues a broker note on GlaxoSmithKline PLC

DZ Bank today reaffirms its buy investment rating on GlaxoSmithKline PLC (LON:GSK) and raised its price target to 2000p (from 1850p).

Broker Forecasts data provided...

Thu, 31/10/2019 - 09:50